Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 03, 2024 08:00 ET | Source: Avalyn Pharma Inc.

Avalyn Announces Initiation of its Global Phase 2b MIST Study of AP01 Inhaled Pirfenidone for Progressive Pulmonary Fibrosis

CAMBRIDGE, Mass., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc., a clinical-stage biopharmaceutical company focused on development of inhaled therapies for treatment of life-threatening...
August 29, 2024 08:00 ET | Source: Avalyn Pharma Inc.

Avalyn to Participate in Multiple Upcoming Investor Conferences

CAMBRIDGE, Mass., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc., a clinical-stage biopharmaceutical company focused on development of inhaled therapies for life-threatening pulmonary...
August 26, 2024 08:00 ET | Source: Avalyn Pharma Inc.

Avalyn Announces Upcoming Presentations on its Lead Program AP01, Inhaled Pirfenidone, for the Treatment of Pulmonary Fibrosis at the European Respiratory Society International Congress 2024

CAMBRIDGE, Mass., Aug. 26, 2024 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc., a clinical-stage biopharmaceutical company focused on development of inhaled therapies for the treatment of life-threatening...
August 12, 2024 08:00 ET | Source: Avalyn Pharma Inc.

Avalyn Announces Initiation of Phase 1b Clinical Study for AP02, its Novel Inhaled Nintedanib

CAMBRIDGE, Mass., Aug. 12, 2024 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc., a clinical-stage biopharmaceutical company focused on development of inhaled therapies for treatment of life-threatening...
August 05, 2024 08:00 ET | Source: Avalyn Pharma Inc.

Avalyn Appoints Erin Lavelle, Seasoned Biopharma Finance Executive, to its Board of Directors

CAMBRIDGE, Mass., Aug. 05, 2024 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc., a clinical-stage biopharmaceutical company focused on development of inhaled therapies for life-threatening pulmonary...
August 01, 2024 08:00 ET | Source: Avalyn Pharma Inc.

Avalyn to Participate in Multiple Upcoming Investor Conferences

CAMBRIDGE, Mass., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc., a clinical-stage biopharmaceutical company focused on development of inhaled therapies for life-threatening pulmonary...
May 28, 2024 08:00 ET | Source: Avalyn Pharma Inc.

Avalyn to Participate in Jefferies Global Healthcare Conference

CAMBRIDGE, Mass., May 28, 2024 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc., a clinical-stage biopharmaceutical company focused on development of inhaled therapies for life-threatening pulmonary diseases,...
May 20, 2024 16:16 ET | Source: Avalyn Pharma Inc.

Avalyn Presents Clinical Data on AP01 for Pulmonary Fibrosis, Including Long-Term Efficacy and Imaging Biomarker Data, at ATS 2024

AP01 (Inhaled Pirfenidone) Treatment Demonstrated Substantially Improved Efficacy and Tolerability Out to 3.5 Years Compared to Historical Data with Oral Pirfenidone Additional Poster Presentations...
May 13, 2024 08:00 ET | Source: Avalyn Pharma Inc.

Avalyn Announces Multiple Presentations on its Lead Program, AP01, for Pulmonary Fibrosis and its Approach to Developing Novel Inhaled Therapies for Lung Diseases at the 2024 American Thoracic Society International Conference

Presentations to Include Long-term Safety and Efficacy Data from the ATLAS Trial Extension Study of AP01 (Inhaled Pirfenidone) for Pulmonary Fibrosis Avalyn to be featured in ATS Mini Theater Program...
May 01, 2024 08:00 ET | Source: Avalyn Pharma Inc.

Avalyn Bolsters Leadership Team with the Appointment of Douglas Carlson as Chief Financial Officer and Chief Business Officer

CAMBRIDGE, Mass., May 01, 2024 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc., a clinical-stage biopharmaceutical company focused on development of inhaled therapies for life-threatening pulmonary diseases,...